相关临床试验
10
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
10.0%
已完成
5
50.0%
招募中
1
10.0%
终止
3
30.0%
暂无批准数据
- Barinthus Bio's VTP-1000, the first antigen-specific immune tolerance therapy for celiac disease utilizing an immunomodulator, demonstrated dose-dependent pharmacological effects and was well-tolerated with no treatment-related serious adverse events in the single ascending dose portion of its Phase 1 AVALON trial. - The trial enrolled 18 patients across three placebo-controlled cohorts, with VTP-1000 showing immune recognition without serious inflammation through observed IL-2 responses at all dose levels. - The multiple ascending dose portion of the trial, which includes a gluten challenge, is ongoing with data expected in the second half of 2026, representing a potential breakthrough for the estimated 80 million people globally affected by celiac disease. - VTP-1000 utilizes Barinthus Bio's proprietary SNAP-TI platform to co-deliver gluten-derived peptide antigens and rapamycin in nanoparticles designed to promote immune tolerance to gluten.
- Barinthus Biotherapeutics and Clywedog Therapeutics have entered into a definitive merger agreement to create a combined company focused on metabolic and autoimmune diseases, with the transaction expected to close in the first half of 2026. - The merged entity will advance three clinical-stage candidates targeting Type 1 diabetes, Type 2 diabetes, and celiac disease, with four key clinical data milestones anticipated within 18 months of closing. - The combined company will operate under the name Clywedog Therapeutics and trade on NASDAQ under ticker "CLYD," with Clywedog shareholders owning approximately 66% and Barinthus Bio shareholders owning 34% of the merged entity. - ChemDiv will continue providing integrated drug discovery services to support the combined company's pipeline, including AI-enabled pharmacology and computational modeling capabilities.
- Biopharma job postings declined 16% year-over-year in Q4 2024, with at least 24,000 industry professionals laid off throughout the year, including major cuts at Johnson & Johnson, Bristol Myers Squibb, and Bayer. - Recent positive developments include venture investment reaching $26 billion across 416 rounds in 2024, up from $23.3 billion in 2023, breaking a two-year downward trend in venture capital spending. - Early 2025 has seen significant deal activity at the J.P. Morgan Healthcare Conference, with Eli Lilly, GSK, Gilead, and Johnson & Johnson announcing deals potentially worth over $15 billion combined.
- A Phase 2a trial shows that imdusiran, VTP-300, and low-dose nivolumab led to significantly greater HBsAg declines in chronic hepatitis B patients. - 23% of participants receiving the combination therapy achieved HBsAg loss by Week 48, indicating a potential path to functional cure. - The triple combination was generally well-tolerated, with no immune-related adverse events reported during the study period. - These findings support the strategy of combining surface antigen reduction with immune reawakening in HBV treatment.
